Department of Obstetrics and Gynaecology, Free Universities of Brussels (VUB-ULB) CHU Saint-Pierre, Hoogstrasse 322, 1000 Brussels, Belgium
1 To whom correspondence should be addressed. e-mail: serge.rozenberg{at}skynet.be
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: breast cancer/HRT/prognosis/systematic review
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In addition to the recent article by Chlebowski et al. (2003), we found 29 studies that met the inclusion criteria. However, we eliminated duplicate publications involving the same cohorts (Squitieri et al., 1994
; Bonnier et al., 1995
; Salmon et al., 1995
; Holli et al., 1997
; Bonnier et al., 1998
; Henrich et al., 1998
). In such cases we selected the article with the highest number of patients (Salmon et al., 1999
; Bonnier et al., 2000
; Gajdos et al., 2000
) or the article that provided the most information (Holli et al., 1998
; LeBlanc et al., 1999
). Finally, we selected 25 studies for which we evaluated the methodology, the characteristics of the studied populations, confounding breast cancer risk factors and prognostic indicators.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Former studies. Among the other 24 studies, there were no randomized trials. Twelve studies were stated to be retrospective by the authors and seven were reported to be prospective; however, for some of these studies only part of the methodology occurred prospectively. We determined that the remaining five studies were retrospective (Table I). The number of patients included varied between 60 and 1480. The number of patients using HRT varied between 29 and 561. In three studies, women using HRT were matched to women not using HRT based on their age at the time of diagnosis. One study compares cases with the general population. Most studies provided information about the age of the patients at diagnosis; however, some mentioned only the age distribution of the patients who were screened. Six studies found that HRT users were younger than non-users, while in one study, HRT users were older than control patients. Generally, the age distributions were younger than in the WHI study. All except five studies mentioned exclusion criteria, although these criteria varied from one study to the next. For instance, the histological criteria varied: some studies included only ductal and lobular invasive cancers (IDC, ILC), while others excluded only lobular carcinoma in situ cancers (LCIS) and not ductal carcinoma in situ (DCIS). Patients with a previous history of breast cancer were excluded in some studies, but not in others (Table I). Three studies among six that analysed the body mass index (BMI) observed that HRT users had, on average, a lower BMI than did the control group (Bonnier et al., 2000; Gajdos et al., 2000
; Aerts et al., 2003
).
|
Influence of HRT on prognostic factors
WHI study. In the WHI trial, a large number of risk factors were controlled (Table I). The prognostic factors that were evaluated are shown in Table II. Tumour size was significantly larger among HRT users who developed breast cancer than among placebo users (mean ± SD: 1.7 cm ± 1.1 versus 1.5 cm ± 0.9; P = 0.04). Similarly, node invasion (25.9% versus 15.8%; P = 0.03) occurred more frequently, and the stage was more advanced in HRT users (regional/metastatic: 25.4% versus 16.0%; P = 0.04). There were no differences in the distribution of histology, grade, or estrogen receptors (ER) and progestin receptors (PR) between HRT and placebo users (Chlebowski et al., 2003).
|
Three studies found that HRT users developed significantly smaller tumours than non-users, when clinically evaluated (Fowble et al., 1999; Bonnier et al., 2000
; Delgado et al., 2001
). Delgado et al. (2001)
also found that HRT users less often had invaded lymph nodes (P < 0.05). Similar results were also found by 10 investigators, when evaluated histologically (Table II). No differences were reported in relation to the duration of HRT use (Magnusson et al., 1996
; Delgado et al., 2001
). However, some authors observed smaller tumours when using combined estrogenprogestin regimens, and less nodal invasion when using unopposed estrogens (P < 0.05) (Delgado et al., 2001
). Three studies showed that HRT users had stage I disease more often than controls (Delgado et al., 2001
; Manjer et al., 2001
; Cheek et al., 2002
). Using subgroup analyses, Delgado et al. (2001)
found a significant increase of stage I diseases in HRT users for 36 months or more. Diel et al. (2002)
observed fewer patients with metastases among HRT users than among non-users (P < 0.001).
The prognostic histological factors are shown in Table II. Contradictory results have been published concerning ER positivity: three studies reported that women using HRT have significantly more tumours expressing ERs (Lower et al., 1999; Gajdos et al., 2000
; Delgado et al., 2001
), but two other studies found the opposite (Cheek et al., 2002
; Sacchini et al., 2002
). In subanalyses, Delgado et al. (2001)
found higher rates of positive ERs among women using combined estrogenprogestin regimens (P = 0.03).
Three studies out of 14 found that HRT users had significantly more frequent tumours with favourable histology (in situ, tubular, medullary, papillary and mucinous carcinoma) (Stolier et al., 1997; Gapstur et al., 1999
; Manjer et al., 2001
), but also more frequent invasive lobular carcinomas (Manjer et al., 2001
; Klein et al., 2003
).
Ten studies out of 17 found that HRT users more frequently had well-differentiated tumours than non-users (Table II). However, in Delgados study, a favourable grade was found particularly in women using a combined HRT regimen (P < 0.05) (Delgado et al., 2001). Two studies evaluated the Nottingham Prognostic Index (which simultaneously assesses the size, nodal invasion and histological grade), but only one study found significantly decreased indices (translating to a better prognosis) among HRT users (Manjer et al., 2001
).
Eight studies evaluated ploidy among HRT users and non-users, but none found a significant difference concerning this parameter between HRT users and non-users.
A significant difference in the amount of cells in S phase, was found in two studies out of seven evaluating this parameter. Nevertheless, these two studies found contradictory results. Holli et al. (1998) found a lower S-phase fraction among HRT users (P < 0.05), and even more so in current users (P = 0.001), while Cobleigh et al. (1999)
found the opposite (P < 0.05) among women who had tumours expressing positive ERs (P < 0.01).
No difference in expression of protein Neu, Bcl-2 gene, protein p53 and E-cadherin could be observed (Holli et al., 1998; OConnor et al., 1998
). Sacchini et al. (2002)
observed significantly more frequent vascular emboli among HRT users (32.7%) than among non-users (23.9%). No difference in the Ki-67 proliferation index could be observed, even after adjustment for age and tumour size. Nevertheless, using subanalyses these authors found that Ki-67 was enhanced in women using HRT for <1 year and diminished in women using HRT for >5 years (Sacchini et al., 2002
). Finally, one study reported increased levels of cathepsin D in women using HRT (95% compared with 59% among control patients), which is known to be associated with a worse prognosis (Jones et al., 1994
). One should note, however, that the increase in cathepsin did not reach the threshold level that indicates a bad prognosis (>60 fmol/mg).
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Few studies have analysed their results in relation to the HRT regimen that was used: limited data suggest that prolonged use of combined regimens are more often associated with better prognosis (Magnusson et al., 1996; Delgado et al., 2001
; Sacchini et al., 2002
). However, again, since these results concern observational studies and subgroups, the interpretation should remain cautious. Furthermore, although only one regimen was evaluated in the WHI study, it concerned a continuous combined regimen.
We also found some contradictory results: for example, the proportion of tumours with positive ERs and a higher S-phase fraction was found to be higher or lower in HRT users by different investigators (Table II). More favourable histology was reported in HRT users, but also more invasive tumours (Gapstur et al., 1999). More recently, seven studies reported that HRT users more frequently develop ILC (Li et al., 2000
; 2003
; Manjer et al., 2001
; Chen et al., 2002
; Daling et al., 2002
; Klein et al., 2003
; Newcomer et al., 2003
). Five studies among these analysed subgroups and reported that the increase in lobular cancers could be attributed to the use of combined HRT regimens (Li et al., 2000
; Chen et al., 2002
; Daling et al., 2002
; Li et al., 2003
; Newcomer et al., 2003
). On the other hand, in the WHI study, no difference could be found for steroid receptors or histological parameters between HRT users and non-users affected by breast cancer, but even in this study the number of women affected by breast cancer was low (n = 309 cases with known ER status) in proportion to the cases that were initially recruited in the cohort (n = 16 608). The proportion of S phase was not reported in the WHI study.
The Ki-67 proliferation index was only reported in one study. These authors suggested that HRT is associated with less invasive tumours (Sacchini et al., 2002). Higher proliferation rates were found in HRT users for <1 year, suggesting that these tumours began their development before the initiation of the HRT, while lower proliferation indices, were detected in long-term users (of >5 years), suggesting that these tumours are less aggressive. Only two studies evaluated new markers of breast cancer prognosis such as Neu protein, and the gene product of Bcl-2, p53 protein and E-cadherin: no differences were found between users and non-users (Holli et al., 1998
; OConnor et al., 1998
).
Finally, to be complete, one should also note that cathepsin D and the presence of vascular emboli, two markers of worsening prognosis, were very rarely studied but were nevertheless reported to be more often associated with HRT use (Jones et al., 1994; Sacchini et al., 2002
). Similarly, LeBlanc et al. (1999)
found that HRT users had more frequently tumours with a bad prognosis (tumours of >2 cm, invaded nodes, negative hormonal receptors) than tumours with a good prognosis (tumours of <2 cm, no node invasion, positive hormonal receptors) than non-users [odds ratio 4.48; 95% confidence interval (CI) 1.1018.30].
While it has been repeatedly cited in the literature that HRT is associated with a benefit in breast cancer prognosis, we cannot rule out the possibility that a publication and/or citation bias has existed in favour of this statement. The data that we found and the WHI study do not permit us to conclude that HRT favourably influences the prognosis of breast cancer. The observational studies provided data that are limited, and often contradictory. The results of the WHI study should be considered as providing a higher degree of evidence, since only this study was a prospective, randomized trial. However, since this study assessed only one particular HRT regimen, its results cannot be considered as definitive. A recent meta-analysis that evaluated the effect of HRT on mortality concluded that the risk of death from breast cancer among post-menopausal women who use HRT is reduced (Nanda et al., 2002), but a borderline increase risk of mortality was found in the Million Women Study Collaborators (relative risk 1.22; 95% CI 1.001.48) (Beral, 2003
). Even in the latter study, however, insufficient data were collected to investigate the relationship between mortality and HRT regimen or duration. It is therefore difficult to provide explanations for these contradictory observations. One has to rule out possible biases influencing lower mortality among estrogen users affected by breast cancer. Alternatively, other prognostic factors, such as ploidy, S-phase fraction, Ki-67 proliferation index, overexepression of protein Neu, p53 protein, Bcl-2 expression, E-cadherin and cathepsin D, as well as vascular emboli, should also be considered. Finally, if the prognosis of breast cancer is investigated prospectively in the future, newly discovered prognostic factors, such as genes expressed by the tumour, should also be added (van de Vijver et al., 2002
; Huang et al., 2003
).
In summary, although only one combined estrogenprogestin HRT regimen (CEE associated with MPA) was studied, the latest results of the WHI trial indicate that breast cancers occur more frequently in women who use this regimen (hazard ratio 1.24). Contrary to what was previously thought and often cited, breast cancer in these HRT users was also associated with some worse prognostic indices, associated with a small increase in size and number of involved lymph nodes, compared with breast cancers occurring in non-HRT users. In view of these data, although no difference in mortality was found in the WHI study, we hypothesize that the reduced mortality that has been reported previously among HRT users in observational studies may be essentially due to biases involving detection and surveillance inherent to the populations that were studied.
We therefore believe that the current clinical message to our patients should be changed, and that one can no longer declare that breast cancers developed while using HRT are of better prognosis and associated with lower mortality.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Beral V and the Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362,419427.[CrossRef][ISI][Medline]
Bergkvist L, Adami HO, Persson I, Bergstrom R and Krusemo UB (1989) Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogenprogestogen replacement therapy. Am J Epidemiol 130,221228.[Abstract]
Bilimoria MM, Winchester DJ, Sener SF, Motykie G, Sehgal UL and Winchester DP (1999) Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Ann Surg Oncol 6,200207.
Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM and Piana L (1995) Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85,1117.
Bonnier P, Bessenay F, Sasco AJ, Beedassy B, Lejeune C, Romain S, Charpin C, Piana L and Martin PM (1998) Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 79,278282.[CrossRef][ISI][Medline]
Bonnier P, Sakr R, Bessenay F, Lejeune C, Charpin C, Martin PM and Piana L (2000) Effects of hormone replacement therapy for menopause on prognostic factors of breast cancer. Gynecol Obstet Fertil 28,745753.[Medline]
Cheek J, Lacy J, Toth-Fejel S, Morris K, Calhoun K and Pommier RF (2002) The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 137,10151019; discussion 10191021.[ISI]
Chen CL, Weiss NS, Newcomb P, Barlow W and White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287,734741.
Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA et al. (2003) WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Womens Health Initiative Randomized Trial. JAMA 289,32433253.
Cobleigh MA, Norlock FE, Oleske DM and Starr A (1999) Hormone replacement therapy and high S phase in breast cancer. JAMA 281,15281530.
Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350,10471059.[CrossRef][ISI][Medline]
Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G et al. (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95,24552464.[CrossRef][ISI][Medline]
Delgado RC and Lubian Lopez DM (2001) Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38,147156.[CrossRef][ISI][Medline]
Diel IJ, Schuetz F, Puschel M, Solomayer EF, Von Holst T, Haus U, Kohnen R and Bastert G (2002) Reduced incidence of metastases in breast cancer patients treated with preoperative hormone replacement therapy (HRT): a retrospective study in 1160 women. The 25th Annual Symposium of San Antonio, December, 2002. Abstract. Available online at: http://sabcs.org/SymposiumOnline/index.aspabstracts
Estève J, Seradour B, Jacquemier J and Remontet L (2002) Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography. J Med Screen 9,7073.[CrossRef][ISI][Medline]
Faiz O and Fentiman IS (1998) Hormone replacement therapy and breast cancer. Int J Clin Pract 52,98101.[ISI][Medline]
Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M and Goldstein L (1999) Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol 17,16801688.
Gajdos C, Tartter PI and Babinszki A (2000) Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol 95,513518.
Gapstur SM, Morrow M and Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Womens Health Study. JAMA 281,20912097.
Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ et al. (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336,17691775.
Grodstein F, Clarkson TB and Manson JE (2003) Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 348,645650.
Harding C, Knox WF, Faragher EB, Baildam A and Bundred NJ (1996) Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ 312,16461647.
Henrich JB, Kornguth PJ, Viscoli CM and Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51,12771283.[CrossRef][ISI][Medline]
Holli K, Isola J and Cuzick J (1997) Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet 350,17041705.[ISI][Medline]
Holli K, Isola J and Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16,31153120.[Abstract]
Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M and Chen CM et al. (2003) Gene expression predictors of breast cancer outcomes. Lancet 361,15901596.[CrossRef][ISI][Medline]
Jernström H, Frenander J, Ferno M and Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80,14531458.[CrossRef][ISI][Medline]
Jones C, Ingram D, Mattes E and Hahnel R (1994) The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Aust 161,106110.[ISI][Medline]
Kavanagh AM, Mitchell H and Giles GG (2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355,270274.[CrossRef][ISI][Medline]
Klein P, Gallinson D, Siegel B, Vallejo C, Kornrich D and Axelrod D (2003) Postmenopausal females who develop breast cancer after using hormone replacement therapy (HRT) have an increased incidence of invasive lobular carcinoma. The ASCO Annual Meeting, May 31 to June 3, 2003 Chicago, IL. Abstract 3583. Available online at: http://www.asco.org/ac/1,1003,_12002138,00.asp
Laya MB, Larson EB, Taplin SH and White E (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88,643649.
LeBlanc ES, Viscoli CM and Henrich JB (1999) Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices. J Womens Health Gend Based Med 8,815823.[CrossRef][ISI][Medline]
Li CI, Weiss NS, Stanford JL and Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88,25702577.[CrossRef][ISI][Medline]
Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL and Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289,32543263.
Lower EE, Blau R, Gazder P and Stahl DL (1999) The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. Breast Cancer Res Treat 58,205211.[CrossRef][ISI][Medline]
Magnusson C, Holmberg L, Norden T, Lindgren A and Persson I (1996) Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38,325334.[ISI][Medline]
Manjer J, Malina J, Berglund G, Bondeson L, Garne JP and Janzon L (2001) Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 92,919922.[CrossRef][ISI][Medline]
Nanda K, Bastian LA and Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186,325334.[CrossRef][ISI][Medline]
Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA and Daling JR (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14, 225233.[CrossRef][ISI][Medline]
OConnor IF, Shembekar MV and Shousha S (1998) Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 51,935938.[Abstract]
Persson I, Yuen J, Bergkvist L and Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogenprogestin replacement therapylong-term follow-up of a Swedish cohort. Int J Cancer 67,327332.[CrossRef][ISI][Medline]
Ross RK, Paganini-Hill A, Wan PC and Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92,328332.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Womens Health Initiative randomized controlled trial. JAMA 288,321333.
Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G and Veronesi U (2002) Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9,266271.
Salmon RJ, Remvikos Y, Ansquer Y and Asselain B (1995) HRT and breast cancer. Lancet 346,17021703.[CrossRef][Medline]
Salmon RJ, Ansquer Y, Asselain B, Languille O, Lesec G and Remvikos Y (1999) Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause. Oncol Rep 6,699703.[ISI][Medline]
Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA and Hoover RN (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91,264270.
Squitieri R, Tartter PI, Ahmed S, Brower ST and Theise ND (1994) Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 178,167170.[ISI][Medline]
Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA and Hole D (2000) Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. BMJ 320,348349.
Stolier AJ, Mera R and Schapira D (1998) The impact of current use of hormone replacement therapy on prognostic factors and surgical treatment of new breast cancers. Oncol Rep 5,6164.[ISI][Medline]
vandeVijver MJ, He YD, vant Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347,19992009.
Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA et al. (2002) Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 100,11481158.
Submitted on July 14, 2003; resubmitted on October 2, 2003; accepted on November 10, 2003.